Eli Lilly continues to see strong growth coming from its GLP-1 drugs. The company's current 2025 guidance looks conservative.

Eli Lilly investors and analysts said they want to hear details from the company on how exactly it plans to grow U.S. sales ...

Eli Lilly on Thursday suggested that demand for its popular diabetes and weight-loss treatments was not a concern, easing ...

Food and drug companies have expressed optimism, but the new health secretary and his MAHA movement will likely make waves.

(Reuters) - Eli Lilly investors and analysts said they want to hear details from the company on how exactly it plans to grow U.S. sales of popular weight-loss drug Zepbound after it last month ...

In the first half of 2025, Ozempic developer Novo Nordisk in Bagsværd, Denmark, expects results from a second phase III trial ...

Eli Lilly expects to provide results from a study in people with obesity and osteoarthritis of the knee in 2025.

On an adjusted basis, the U.S. drugmaker expects to earn between $22.50 and $24.00 per share in 2025. Analysts were expecting ...

Novartis, Eli Lilly and more put on their deal-making caps, Bristol Myers Squibb targets $2 billion in savings through 2027, ...

In fact, Novo Nordisk recently reported positive results for one of its anti-obesity candidates that puts its current ...

US-based pharmaceutical company Eli Lilly is planning to launch Mounjaro, an anti-diabetes and weight loss drug in India by 2025 after regulatory approvals, reported News18 citing officials from ...

The results were consistent with the preliminary results Eli Lilly shared in January, which disappointed investors.